FindTrial
Sign In

Observational cohort study on the efficacy and safety of Crisugabalin Besilate Capsules in treating neuropathic pain based on pain mechanisms in the real world

Observational cohort study on the efficacy and safety of Crisugabalin Besilate Capsules in treating neuropathic pain based on pain mechanisms in the real world

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113639
Enrollment
Unknown
Registered
2025-12-01
Start date
2025-12-05
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain

Interventions

Exposed Group:None

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients who have been clinically diagnosed with DPNP, PHN, and other neuropathic pain; 2.The treatment plan includes the initial use of Crisugabalin Besilate Capsules; 3.Age >= 18 years old; 4.Capable of understanding and willing to sign a written Informed Consent Form (ICF);

Exclusion criteria

Exclusion criteria: 1.Participated in any other clinical study within 30 days prior to screening. 2.The researcher determines that there are other situations that make the participant unsuitable for participating in this study

Design outcomes

Primary

MeasureTime frame
At week 4 of treatment initiation,Simple McGill Pain Questionnaire (SF-MPQ) compared to the baseline were evaluated;—

Secondary

MeasureTime frame
Adverse event(AE);NRS scale compared to the baseline were evaluated;At week 2 of treatment initiation,Simple McGill Pain Questionnaire (SF-MPQ) compared to the baseline were evaluated;—

Countries

China

Contacts

Public ContactFan Bifa

China-Japan Friendship Hospital

fbf1616@yeah.net+86 15010101616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026